Über uns

The 4TEEN4 Pharmaceuticals GmbH is a company with a clear mission: Improving the management of critically ill patients (e.g. in sepsis, cardiogenic shock, severe trauma). Based on data that prove the reliability of DPP3 as a cardiac depressant factor associated with short-term patient outcome, 4TEEN4 identified DPP3 as a druggable target. The long-term vision is to provide a therapeutic solution for critically ill patients that neutralizes circulating DPP3 in order to restore proper organ function and improve survival. To achieve this mission, 4TEEN4 develops monoclonal antibody therapies accompanied by targeted diagnostic assays. The 4TEEN4 Pharmaceuticals GmbH was established in 2013 and is located in Hennigsdorf, nearby Berlin, Germany.